{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T17:41:06Z","timestamp":1788716466156,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tuberculosis (TB) reactivation has been increasingly identified following immune checkpoint inhibitor (ICI) therapy for cancer patients. However there has been no report on TB reactivation in the gastrointestinal tract. In the report, we describe a patient who developed TB ileitis after pembrolizumab for her metastatic nasopharyngeal carcinoma (NPC). Rechallenge with pembrolizumab after its temporary interruption together with anti-TB therapy produced continuous tumor response but without further TB reactivation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 29-year-old lady with metastatic NPC involving the cervical nodes, lungs and bones started pembrolizumab after failure to multiple lines of chemotherapy. She complained of sudden onset of abdominal pain, vomiting and bloody diarrhea with mucus 21\u00a0months after pembrolizumab. Colonoscopy revealed terminal ileitis with multiple caseating granulomas with Langerhan cells. Serum interferon gamma release assay was strongly positive. She was treated with anti-TB medication and was later rechallenged with pembrolizumab for her progressive lung metastases without further TB relapse while her lung metastases were brought under control again.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>To date, this is the first gastrointestinal TB reactivation after ICI therapy for cancer. Guidelines to screen for TB before initiation of ICIs in endemic areas should be established.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-06845-7","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T12:12:12Z","timestamp":1636546332000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report"],"prefix":"10.1186","volume":"21","author":[{"given":"Kin-Sang","family":"Lau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben Man-Fei","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-On","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sum-Yin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-Ming","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Fai","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan Fan-Ngai","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora Lai-Wan","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chung","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"To-Wai","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai-Yee","family":"Luk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Wing-Mui","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwok-Keung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6283-978X","authenticated-orcid":false,"given":"Victor Ho-Fun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"key":"6845_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","volume":"23","author":"J Sunshine","year":"2015","unstructured":"Sunshine J, Taube JM. PD-1\/PD-L1 inhibitors. Curr pin Pharmacol. 2015;23:32\u20138.","journal-title":"Curr pin Pharmacol"},{"key":"6845_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348.","journal-title":"Eur J Cancer"},{"issue":"4","key":"6845_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3109\/0284186X.2015.1125017","volume":"55","author":"JJ Lee","year":"2016","unstructured":"Lee JJ, Chan A, Tang T. Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin\u2019s lymphoma. Acta Oncol. 2016;55(4):519\u201320.","journal-title":"Acta Oncol"},{"issue":"8","key":"6845_CR4","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1016\/j.jtho.2017.03.012","volume":"12","author":"YC Chu","year":"2017","unstructured":"Chu YC, Fang KC, Chen HC, Yeh YC, Tseng CN, Chou TY, et al. Pericardial tamponade caused by a hypersensitivity response to tuberculosis reactivation after anti-PD-1 treatment in a patient with advanced pulmonary adenocarcinoma. J Thorac Oncol. 2017;12(8):e111\u20134.","journal-title":"J Thorac Oncol"},{"key":"6845_CR5","first-page":"122","volume":"24","author":"K Fujita","year":"2018","unstructured":"Fujita K, Uchida N, Horimoto K, Hashimoto M, Nakatani K, Moriyoshi K, et al. Two cases of cavitary lung cancer with concomitant chronic infectious disease. Respir Med Case Rep. 2018;24:122\u20134.","journal-title":"Respir Med Case Rep"},{"issue":"3","key":"6845_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.cmi.2017.12.003","volume":"24","author":"H Picchi","year":"2018","unstructured":"Picchi H, Mateus C, Chouaid C, Besse B, Marabelle A, Michot JM, et al. Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment. Clin Microbiol Infect. 2018;24(3):216\u20138.","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"6845_CR7","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1080\/0284186X.2018.1433877","volume":"57","author":"KH Jensen","year":"2018","unstructured":"Jensen KH, Persson G, Bondgaard AL, P\u00f8hl M. Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer. Acta Oncol. 2018;57(8):1127\u20138.","journal-title":"Acta Oncol"},{"key":"6845_CR8","doi-asserted-by":"publisher","first-page":"7423","DOI":"10.2147\/OTT.S178246","volume":"11","author":"W He","year":"2018","unstructured":"He W, Zhang X, Li W, Kong C, Wang Y, Zhu L, et al. Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report. OncoTargets Ther. 2018;11:7423\u20137.","journal-title":"OncoTargets Ther"},{"issue":"1","key":"6845_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jiac.2018.06.016","volume":"25","author":"S Takata","year":"2019","unstructured":"Takata S, Koh G, Han Y, Yoshida H, Shiroyama T, Takada H, et al. Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents. J Infect Chemother. 2019;25(1):54\u20138.","journal-title":"J Infect Chemother"},{"issue":"1","key":"6845_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/qjmed\/hcy243","volume":"112","author":"CC Tsai","year":"2019","unstructured":"Tsai CC, Chen JH, Wang YC, Chang FY. Re-activation of pulmonary tuberculosis during anti-programmed death-1 (PD-1) treatment. QJM. 2019;112(1):41\u20132.","journal-title":"QJM"},{"key":"6845_CR11","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3389\/fonc.2019.00659","volume":"9","author":"R van Eeden","year":"2019","unstructured":"van Eeden R, Rapoport BL, Smit T, Anderson R. Tuberculosis infection in a patient treated with nivolumab for non-small cell lung cancer: case report and literature review. Front Oncol. 2019;9:659.","journal-title":"Front Oncol"},{"issue":"4","key":"6845_CR12","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1080\/17843286.2019.1629078","volume":"75","author":"V Inthasot","year":"2020","unstructured":"Inthasot V, Bruyneel M, Muylle I, Ninane V. Severe pulmonary infections complicating nivolumab treatment for lung cancer: a report of two cases. Acta Clin Belg. 2020;75(4):308\u201310.","journal-title":"Acta Clin Belg"},{"issue":"475","key":"6845_CR13","doi-asserted-by":"publisher","first-page":"eaat2702","DOI":"10.1126\/scitranslmed.aat2702","volume":"11","author":"DL Barber","year":"2019","unstructured":"Barber DL, Sakai S, Kudchadkar RR, Fling SP, Day TA, Vergara JA, et al. Tuberculosis following PD-1 blockade for cancer immunotherapy. Sci Transl Med. 2019;11(475):eaat2702.","journal-title":"Sci Transl Med."},{"issue":"7","key":"6845_CR14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/CJI.0000000000000324","volume":"43","author":"JS Song","year":"2020","unstructured":"Song JS, Jeffery CC. Laryngeal tuberculosis in a patient on avelumab for metastatic nasopharyngeal carcinoma. J Immunother. 2020;43(7):222\u20133.","journal-title":"J Immunother"},{"issue":"1","key":"6845_CR15","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/S1470-2045(19)30674-6","volume":"21","author":"EA Langan","year":"2020","unstructured":"Langan EA, Graetz V, Allerheiligen J, Zillikens D, Rupp J, Terheyden P. Immune checkpoint inhibitors and tuberculosis: an old disease in a new context. Lancet Oncol. 2020;21(1):e55-65.","journal-title":"Lancet Oncol"},{"issue":"4","key":"6845_CR16","doi-asserted-by":"publisher","first-page":"e000866","DOI":"10.1136\/esmoopen-2020-000866","volume":"5","author":"K Anand","year":"2020","unstructured":"Anand K, Sahu G, Burns E, Ensor A, Ensor J, Pingali SR, et al. Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors. ESMO Open. 2020;5(4):e000866.","journal-title":"ESMO Open."},{"issue":"6","key":"6845_CR17","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"36","key":"6845_CR18","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","volume":"35","author":"C Hsu","year":"2017","unstructured":"Hsu C, Lee SH, Ejadi S, Even C, Cohen RB, Le Tourneau C, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol. 2017;35(36):4050\u20136.","journal-title":"J Clin Oncol"},{"key":"6845_CR19","unstructured":"Centre for Health Protection. Notification & death rate of tuberculosis (all forms), 1947-2019. Available from: https:\/\/www.chp.gov.hk\/en\/statistics\/data\/10\/26\/43\/88.html. Assessed 30 Dec 2020."},{"key":"6845_CR20","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1146\/annurev-immunol-032712-095939","volume":"31","author":"A O'Garra","year":"2013","unstructured":"O\u2019Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. The immune response in tuberculosis. Annu Rev Immunol. 2013;31:475\u2013527.","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"6845_CR21","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/thx.2005.046797","volume":"60","author":"British Thoracic Society Standards of Care Committee","year":"2005","unstructured":"British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax. 2005;60(10):800\u20135.","journal-title":"Thorax"},{"issue":"1","key":"6845_CR22","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12890-020-01274-9","volume":"20","author":"PH Wang","year":"2020","unstructured":"Wang PH, Lin CH, Chang TH, Wu CS. Chest roentgenography is complementary to interferon-gamma release assay in latent tuberculosis infection screening of rheumatic patients. BMC Pulm Med. 2020;20(1):232.","journal-title":"BMC Pulm Med"},{"key":"6845_CR23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/1471-2334-9-207","volume":"9","author":"EY Kim","year":"2009","unstructured":"Kim EY, Lim JE, Jung JY, Son JY, Lee KJ, Yoon YW, et al. Performance of the tuberculin skin test and interferon-gamma release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population. BMC Infect Dis. 2009;9:207.","journal-title":"BMC Infect Dis"},{"key":"6845_CR24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ijid.2019.12.012","volume":"91","author":"C Della Bella","year":"2020","unstructured":"Della Bella C, Spinicci M, Alnwaisri HFM, Bartalesi F, Tapinassi S, Mencarini J, et al. LIOFeronTB\/LTBI: A novel and reliable test for LTBI and tuberculosis. Int J Infect Dis. 2020;91:177\u201381.","journal-title":"Int J Infect Dis"},{"issue":"5","key":"6845_CR25","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jinf.2019.08.018","volume":"79","author":"G Sotgiu","year":"2019","unstructured":"Sotgiu G, Saderi L, Petruccioli E, Aliberti S, Piana A, Petrone L, et al. QuantiFERON TB Gold Plus for the diagnosis of tuberculosis: a systematic review and meta-analysis. J Infect. 2019;79(5):444\u201353.","journal-title":"J Infect"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06845-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06845-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06845-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T12:12:48Z","timestamp":1636546368000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06845-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6845"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06845-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,10]]},"assertion":[{"value":"18 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient provided a written informed consent for the personal and clinical details along with any identifying images to be published in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1148"}}